<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859352</url>
  </required_header>
  <id_info>
    <org_study_id>D9831C00008</org_study_id>
    <secondary_id>EudraCT No. 2008-008224-32</secondary_id>
    <nct_id>NCT00859352</nct_id>
  </id_info>
  <brief_title>AZD1981 Midazolam CYP4503A Induction Study</brief_title>
  <official_title>A Phase I, Open, Randomised, Non-Comparative, Parallel Group Study of a Potential Cytochrome P450 3A Induction After Repeat Twice Daily Oral Dosing With 100 and 500 mg AZD1981 Tablets for 14 Days to Healthy Male Volunteers With Single Oral Doses of Midazolam 7.5 mg.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to investigate if the exposure of midazolam is
      clinically significantly changed by 14 days of exposure to AZD1981 through possible enzyme
      induction of CYP3A.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK samples for both AZD1981 and Midazolam.</measure>
    <time_frame>Intense PK-sampling during 3 pre-defined study days for PK profiling and some sampling throughout the whole study period for confirmatory purposes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sampling of 4β-hydroxycholesterol</measure>
    <time_frame>Taken at baseline and after steady state of AZD1981</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety variables (adverse events and laboratory safety lab)</measure>
    <time_frame>Adverse events taken during study and safety lab at a few time points</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Healthy Male Volunteer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981 100mg and Midazolam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981 500mg and Midazolam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981</intervention_name>
    <description>oral tablets during 14 consecutive days.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Each subject will receive two single doses of 7.5 mg midazolam given as oral solution. The Midazolam dose will be given on Day 1 and on day 16.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Have a body mass index between 19 and 30 kg/m2 and weigh at least 50 kg and no more
             than 100 kg

          -  Be a non-smoker or ex-smoker who has stopped smoking for &gt;6 months prior to Visit 1
             (pre-entry)

        Exclusion Criteria:

          -  Any clinically significant disease or disorder which, in the opinion of the
             investigator, may either put the subject at risk because of participation in the
             study, or influence the result of the study, or the subject´s ability to participate

          -  Any clinically relevant abnormal findings in phys.examination, clinical chemistry,
             haematology, urinalysis, vital signs, or ECG at baseline which, in the opinion of the
             investigator, may put the subject at risk because of his participation in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Pettersson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, Lund, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aslak Rautio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Hermelinen AB, Luleå, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2009</study_first_submitted>
  <study_first_submitted_qc>March 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2009</study_first_posted>
  <last_update_submitted>April 9, 2009</last_update_submitted>
  <last_update_submitted_qc>April 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Christer Hultquist, Medical Science Director</name_title>
    <organization>AstraZeneca R&amp;D Lund, Sweden</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

